Clinical Trial

Effects of Lacticaseibacillus Rhamnosus LRa05 on Bacterial Vaginosis and Ovarian Function in Women

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 19, 2025 (before its estimated October 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
In this study, Lacticaseibacillus rhamnosus LRa05 was selected as test preparations to observe the clinical efficacy in the intervention trial of combined antibiotic therapy, and to evaluate its effects on the cure rate, recurrence rate and vaginal microbiota of patients with bacterial vaginitis.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-02-06.
Trial Details
NCT Number NCT06821789
Lead Sponsor Wecare Probiotics Co., Ltd.
Conditions Patients With Bacterial Vaginosis
Enrollment 60 participants
Start Date 2025-03-15
Primary Completion 2025-10-30 (estimated)
Study Completion 2026-05-30 (estimated)
Updated on ClinicalTrials.gov 2025-02-19